When deprescribing, professionals may not only consider the reduction of insulin doses and the simplification of complex insulin regimes but also stopping sulfonylurea treatment and starting an antidiabetic that does not induce hypoglycemia [3,4,5,6,20,21,22]. This evidence concerns the gene INS and Hypoglycemia.